Spots Global Cancer Trial Database for advanced solid cancers
Every month we try and update this database with for advanced solid cancers cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | NCT00676299 | Protein Kinase ... Antineoplastic ... Clinical Trial,... Maximum Tolerat... Pharmacokinetic... Advanced Malign... Solid Malignanc... | JNJ-26483327 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | NCT03956680 | Advanced Solid ... | BMS-986301 Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| TrasGEX™: Phase 1 Study in Cancer Patients | NCT01409343 | Solid Tumors | TrasGEX™ | 18 Years - | Glycotope GmbH | |
| A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors | NCT02792465 | Advanced Solid ... Breast Cancer | CFI-402257 Fulvestrant | 18 Years - | University Health Network, Toronto | |
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | NCT05054374 | Breast Cancer Breast Cancer S... HER2-negative B... Solid Carcinoma MEK1 Gene Mutat... MEK2 Gene Mutat... Metastatic Brea... | Mirdametinib Fulvestrant | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy | NCT02694822 | Advanced Solid ... Advanced Solid ... | AGEN1884 | 18 Years - | Agenus Inc. | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | NCT00337376 | Advanced Solid ... | Rapamune Abraxane | 18 Years - | Yale University | |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors | NCT02257476 | Neoplasms Malignancies | Carfilzomib Dexamethasone | 18 Years - | Emory University | |
| AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy | NCT02694822 | Advanced Solid ... Advanced Solid ... | AGEN1884 | 18 Years - | Agenus Inc. | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain | NCT00478101 | Advanced Solid ... | oxycodone fenta... | 19 Years - | Gachon University Gil Medical Center | |
| TrasGEX™: Phase 1 Study in Cancer Patients | NCT01409343 | Solid Tumors | TrasGEX™ | 18 Years - | Glycotope GmbH | |
| CetuGEX™: Phase 1 Study in Cancer Patients | NCT01222637 | Solid Tumors | CetuGEX™ | 18 Years - | Glycotope GmbH | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study | NCT00096941 | Solid Cancers | Pertuzumab | - | Genentech, Inc. | |
| Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer | NCT01019941 | Advanced Solid ... | CKD-810, Taxote... CKD-810, Taxote... | 18 Years - | Chong Kun Dang Pharmaceutical | |
| Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain | NCT00478101 | Advanced Solid ... | oxycodone fenta... | 19 Years - | Gachon University Gil Medical Center | |
| An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | NCT03956680 | Advanced Solid ... | BMS-986301 Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | NCT03254732 | Advanced Solid ... | ADI PEG20 Pembrolizumab | 18 Years - | Polaris Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
